Stock Forecast

  Humacyte, Inc. ( HUMA) Stock. Should you Buy or Sell?    $ 4.51

-0.14 (-3.20 %)



Humacyte, Inc. Analysis

Updated on 10-09-2022
Symbol HUMA
Price $4.51
Beta 0.000
Volume Avg. $428.83 thousand
Market Cap $464.56 M
52 Week Range $3.07 - $16.95


Humacyte, Inc. opened the day at $4.51 which is -3.20 % on yesterday's close. Humacyte, Inc. has a 52 week high of $16.95 and 52 week low of $3.07, which is a difference of $13.88. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $464.56 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Humacyte, Inc. for $464.56 M, it would take 15 years to get your money back. Humacyte, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Humacyte, Inc. Stock Forecast - Is Humacyte, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreBuy
ROA ScoreBuy
DE ScoreBuy
PE ScoreBuy
PB ScoreStrong Buy
Overall RecommendationStrong Buy

Growth and Value


PE Ratio 18.040
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Humacyte, Inc.


Price Book Value Ratio 3.266 Price To Book Ratio 3.266
Price To Sales Ratio 0.000 Price Earnings Ratio 87.569


How liquid is Humacyte, Inc.


Current Ratio 17.456
Quick Ratio 17.213


Debt


Debt Ratio 0.423 Debt Equity Ratio 0.732
Long Term Debt To Capitalization 0.127 Total Debt To Capitalization 0.138



Latest news about Humacyte, Inc.


Humacyte, Inc.'s (HUMA) CEO Dr. Laura Niklason on Q2 2022 Results - Earnings Call Transcript

Humacyte, Inc. (NASDAQ:HUMA ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Lauren Marek - LifeSci Advisors, IR Dr. Laura Niklason - President and CEO Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Dr. Heather Prichard - Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer Josh Jennings - Cowen Bruce Jackson - The Benchmark Company Operator Good morning, ladies and gentlemen. And welcome to the Humacyte Second Quarter 2022 Results Conference Call.

Date : 12/08/2022

Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022

DURHAM, N.C., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the second quarter ended June 30, 2022, on Friday, August 12, 2022. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.

Date : 05/08/2022

Humacyte to Present at the H.C. Wainwright Global Investment Conference

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Dale Sander, Chief Financial Officer, and Heather Prichard, Ph.D., Chief Operating Officer, will deliver a corporate presentation in-person at the H.C. Wainwright Global Investment Conference taking place both virtually and in-person at the Fontainebleau Hotel in Miami, on May 24, 2022, at 10:30 a.m. ET.

Date : 16/05/2022

Humacyte, Inc. (HUMA) CEO Laura Niklason on Q1 2022 Results - Earnings Call Transcript

Humacyte, Inc. (NASDAQ:HUMA ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Lauren Marek - Investor Relations Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Heather Prichard - Chief Operating Officer Conference Call Participants Ryan Zimmerman - BTIG Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Bruce Jackson - The Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Humacyte First Quarter 2022 Results Conference Call. Currently, all participants are in a listen-only mode.

Date : 13/05/2022

Humacyte Announces Date of Annual Shareholder Meeting

DURHAM, N.C., April 04, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that its 2022 annual meeting of shareholders will be held virtually on Thursday, June 9, 2022, at 7:30 AM eastern time.

Date : 04/04/2022





About Humacyte, Inc.


CEO :
Sector : Healthcare
Industry : Biotechnology

Website : https://www.humacyte.com

Exchange : NASDAQ Global Select

Description :

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.


My Newsletter

Sign Up For Updates & Newsletters